All MET-097i articles
-
News
Pfizerās Metsera hunger sees it beat Novo Nordiskās obesity biopharma offer
The deal puts Pfizerās plans to acquire the US firm, and a portfolio that includes injectable GLP-1 drugs, back on track.
-
News
Pfizer and Novo Nordisk battle for obesity market dominance
Novo Nordiskās āboldā $6.5 billion bid subject to a final verdict by Metseraās board of directors.
-
NewsPfizer acquires Metsera and its GLP-1 candidates in new $4.9bn obesity play
The deal with the US biopharma adds a portfolio of clinical-stage incretin and amylin research programmes to its pipeline.